What changed
Deals & ownershipOn November 3 and 4, 2026, Regeneron Pharmaceuticals insiders reported option exercises, share sales, and gifts. Director Huda Y. Zoghbi and vice president and controller Jason Pitofsky exercised options and sold shares, while co-chief scientific officer Andrew J. Murphy gifted shares.

Deals & ownershipBetween November 2 and November 4, 2026, executives and directors of Regeneron Pharmaceuticals, Inc. filed reports detailing completed trades and proposed future stock sales. These filings reflect insider activity involving stock option exercises and the subsequent disposal of securities.

What changedRegeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.1 billion, up 36.3% from a year earlier. Net income rose 33.5% to $1.9 billion. Regeneron also expanded its collaboration agreement with Sanofi, receiving $1.0 billion in up-front payments.

Deals & ownershipRegeneron Pharmaceuticals co-chief scientific officer Andrew J. Murphy exercised 17,000 stock options on October 13 and sold 4,147 shares on October 14. The trades occurred under a pre-approved trading plan, reflecting a standard schedule to cover tax obligations and exercise option rights.

What changedRegeneron signed the Sixth Amendment to its Sanofi agreement, received a $1.0 billion upfront and may earn up to $7.0 billion on milestone achievement; it also disclosed a $22 million charge that will lower earnings per share (EPS) by about $0.18.

Upcoming events
As announced by the companies, read by code from their press releases, 8-Ks and official feeds; each date links its announcement. Companies can change dates. Dividends: common shares only; under T+1 settlement the ex-dividend date is normally the record date. Corporate calendar →
Company history
October 2026
REGENERON PHARMACEUTICALS, INC.: 12 recorded developments from 1 official source in 2026-10.
- 2026-10-30: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), quarter 2026-07-01 to 2026-09-30: 5,115,800,000 USD (5.1 billion; 5,116 million); same period a year earlier (2025-07-01 to 2025-09-30): 3,754,300,000 USD (3.8 billion; 3,754 million); change +36.3% Source
- 2026-10-30: Revenue (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), year to date 2026-01-01 to 2026-09-30: 13,011,900,000 USD (13 billion; 13,012 million); same period a year earlier (2025-01-01 to 2025-09-30): 10,458,600,000 USD (10.5 billion; 10,459 million); change +24.4% Source
- 2026-10-30: Operating income (us-gaap:OperatingIncomeLoss), quarter 2026-07-01 to 2026-09-30: 2,048,200,000 USD (2 billion; 2,048 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,026,800,000 USD (1 billion; 1,027 million); change +99.5% Source
- 2026-10-30: Operating income (us-gaap:OperatingIncomeLoss), year to date 2026-01-01 to 2026-09-30: 3,984,600,000 USD (4 billion; 3,985 million); same period a year earlier (2025-01-01 to 2025-09-30): 2,698,000,000 USD (2.7 billion; 2,698 million); change +47.7% Source
- 2026-10-30: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 1,948,700,000 USD (1.9 billion; 1,949 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,460,000,000 USD (1.5 billion; 1,460 million); change +33.5% Source
- 2026-10-30: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 3,972,800,000 USD (4 billion; 3,973 million); same period a year earlier (2025-01-01 to 2025-09-30): 3,660,300,000 USD (3.7 billion; 3,660 million); change +8.5% Source
- 2026-10-30: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 1,794,700,000 USD (1.8 billion; 1,795 million); same period a year earlier (2025-07-01 to 2025-09-30): 1,475,000,000 USD (1.5 billion; 1,475 million); change +21.7% Source
- 2026-10-30: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-30: 4,969,800,000 USD (5 billion; 4,970 million); same period a year earlier (2025-01-01 to 2025-09-30): 4,224,100,000 USD (4.2 billion; 4,224 million); change +17.7% Source
- 2026-10-30: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 3,675,300,000 USD (3.7 billion; 3,675 million); same period a year earlier (2025-01-01 to 2025-09-30): 3,808,200,000 USD (3.8 billion; 3,808 million); change -3.5% Source
- 2026-10-30: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 3,659,100,000 USD (3.7 billion; 3,659 million); previous balance (2025-12-31): 3,118,100,000 USD (3.1 billion; 3,118 million); change +17.4% Source
- 2026-10-30: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 10,906,700,000 USD (10.9 billion; 10,907 million); previous balance (2025-12-31): 9,301,800,000 USD (9.3 billion; 9,302 million); change +17.3% Source
- 2026-10-30: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 33,498,500,000 USD (33.5 billion; 33,499 million); previous balance (2025-12-31): 31,256,900,000 USD (31.3 billion; 31,257 million); change +7.2% Source
September 2026
REGENERON PHARMACEUTICALS, INC.: 2 recorded developments from 1 official source in 2026-09.
- REGENERON PHARMACEUTICALS INC contract modification P00018 action date was 2026-09-25 Source
- 2026-09-25: Department of Health and Human Services awarded contract to REGENERON PHARMACEUTICALS INC Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The Company plans to initiate a Phase 3 study in POTS in the first half of 2027, pending regulatory feedback.
Said October 30, 2026 · Period named: first half of 2027 · Source · Our article
Not yet checked against later reports.
The company has a supplemental Biologics License Application for Libtayo under review by the FDA with a target action date in March 2027.
Said October 30, 2026 · Period named: March 2027 · Source · Our article
Not yet checked against later reports.
The Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031.
Said October 30, 2026 · Period named: 2027 through 2031 · Source · Our article
Not yet checked against later reports.
The Company plans to initiate a Phase 3 study in metabolic dysfunction-associated steatohepatitis (MASH)/MASLD in the fourth quarter of 2026.
Said October 30, 2026 · Period named: fourth quarter of 2026 · Source · Our article
Not yet checked against later reports.
The FDA target action date for the Ordspono (odronextamab) BLA resubmission is in February 2027.
Said October 30, 2026 · Period named: February 2027 · Source · Our article
Not yet checked against later reports.
The Company plans to present interim results from its RNAi therapy study for metabolic dysfunction-associated steatotic liver disease (MASLD) at the AASLD Meeting in November 2026.
Said October 30, 2026 · Period named: November 2026 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Changes in risk factors
The 10-Q filed October 30, 2026 compared with the 10-Q filed July 30, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (4)
- the United States, we continue to rely in considerable part on Sanofi's sales and marketing organization in such jurisdictions. Sanofi also leads or will lead the commercialization efforts for the other products and product candidates subject to the Antibody Collaboration, which now includes four new product candidates pursuant to the recent amendment to the Antibody Collaboration discussed under Part I, Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations – Collaboration, License, and Other Agreements – Sanofi."
- In particular, our business activities outside the United States (which have recently expanded and continue to expand due to, in part, our efforts to establish further commercialization capabilities in certain jurisdictions outside the United States) are subject
- imports from all trading partners under Section 122 of the Trade Act of 1974 ("Section 122"). This surcharge expired on July 24, 2026.
Dropped (6)
- provisions of the agreement governing the Antibody Collaboration (the "Collaboration Agreement"). These provisions concern Sanofi's obligation to provide Regeneron with full access to material information relating to the commercialization of Dupixent or other products commercialized pursuant to the Collaboration Agreement and Regeneron's audit rights under the Collaboration Agreement. It is not possible to determine what impact (if any) the Antibody Collaboration Litigation may have on the Antibody Collaboration and our business relationship with Sanofi, or whether we will be successful in…
- The federal civil False Claims Act prohibits any person from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement
- Civil monetary penalties can be applied if we fail to pay the required rebate, if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| September 30, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| November 17, 2026 | Murphy Andrew J | Planned sale 10b5-1 plan | 5,011 | — | $4,773,278 | SEC |
| November 17, 2026 | George L. Sing | Planned sale | 1,000 | — | $957,687 | SEC |
| November 16, 2026 | George L. Sing | Planned sale | 1,000 | — | $960,264 | SEC |
| November 16, 2026 | McCourt Marion | Planned sale 10b5-1 plan | 566 | — | $545,239 | SEC |
| November 4, 2026 | Jason Pitofsky | Sale | 4,062 | $942.19 | $3,827,159 | SEC |
| November 4, 2026 | Jason Pitofsky | Planned sale | 3,883 | — | $3,789,808 | SEC |
| November 3, 2026 | Huda Y Zoghbi | Sale notice filed | 7,439 | $970.46 | $7,219,274 | SEC |
| November 2, 2026 | George L Sing | Sale notice filed | 21,129 | $964.38 | $20,376,358 | SEC |
| November 2, 2026 | Christine A Poon | Sale | 7,830 | $969.09 | $7,587,958 | SEC |
| November 2, 2026 | Joseph J Larosa | Sale notice filed | 4,466 | $965.49 | $4,311,890 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 8,849,583 | $6,710,372,953 | -2.9% | Q3 2026 |
| State Street | 4,881,362 | $3,701,390,364 | +1.0% | Q3 2026 |
| Geode Capital Management | 2,632,826 | $1,992,068,413 | +0.3% | Q3 2026 |
| Wellington Management | 1,271,957 | $964,486,836 | +0.1% | Q3 2026 |
| Fidelity (FMR) | 1,035,204 | $784,964,318 | +24.4% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 1,172,808 | $731,292,700 | — | Q2 2026 |
| Two Sigma Investments | 869,505 | $659,319,556 | +32.5% | Q3 2026 |
| Citadel Advisors | 352,728 | $267,463,060 | +512.3% | Q3 2026 |
| Renaissance Technologies | 272,218 | $206,414,743 | +83.7% | Q3 2026 |
| Millennium Management | 147,538 | $111,873,639 | -10.6% | Q3 2026 |
| Bridgewater Associates | 105,934 | $80,326,574 | +106.4% | Q3 2026 |
| Capital Research Global Investors | 101,891 | $78,724,785 | — | Q1 2026 |
| D. E. Shaw & Co. | 58,636 | $44,461,919 | +52.4% | Q3 2026 |
| T. Rowe Price | 1,103,865 | $837,028 | -27.8% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.